MSLN Correlates With Immune Infiltration and Chemoresistance as a Prognostic Biomarker in Ovarian Cancer

被引：16
作者：
Li, Yike [1 ,2 ,3 ]
Tian, Wanjia [1 ,3 ]
Zhang, Hong [2 ]
Zhang, Zhijian [2 ]
Zhao, Qinghe [1 ]
Chang, Lei [1 ]
Lei, Ningjing [2 ]
Zhang, Weiwei [1 ]
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Gynecol, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Sch Basic Med Sci, Zhengzhou, Peoples R China
[3] Zhengzhou Univ, Acad Med Sci, Zhengzhou, Peoples R China
来源：
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词：
mesothelin; ovarian cancer; prognostic biomarker; chemoresistance; bioinformatics analysis; MESOTHELIN; EXPRESSION; CELLS; PROLIFERATION; IMMUNOTHERAPY; CHEMOTHERAPY; BEVACIZUMAB; CHECKPOINT; ANTITUMOR; PATTERNS;
D O I：
10.3389/fonc.2022.830570
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Mesothelin (MSLN) is a glycoprotein with various expression degrees in different tumors including mesothelioma, ovarian cancer, pancreatic cancer, etc. MSLN is considered to play an important role in cell survival, proliferation, and tumor progression. Although the expression of MSLN in tumors makes it a potential therapeutic target, its mechanism of action is still unclear, especially its correlation with immune cells infiltration in the tumor microenvironment has not been investigated. In this study, we detected the overexpression of MSLN in ovarian cancer using database analysis and tissue-array staining. We further evaluated the diagnostic value of MSLN and found it was associated with poor overall survival in ovarian cancer. In addition, the high expression of MSLN was significantly related to the immune-related genes and chemoresistant genes. We confirmed the overexpression of MSLN in the chemoresistant ovarian cancer cell lines. Our research suggests that MSLN participates in a variety of pathways related to the suppression of immune activation and promotion of chemoresistance, leading to a poor prognosis in ovarian cancer.
引用
收藏
页数：13
相关论文
共 54 条
[31]   Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer [J].
Monk, BJ ;
Choi, DC ;
Pugmire, G ;
Burger, RA .
GYNECOLOGIC ONCOLOGY, 2005, 96 (03) :902-905
[32]  
Mota Alba, 2020, EJC Suppl, V15, P16, DOI 10.1016/j.ejcsup.2019.11.001
[33]   Origins based clinical and molecular complexities of epithelial ovarian cancer [J].
Muinao, Thingreila ;
Pal, Mintu ;
Boruah, Had Prasanna Deka .
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2018, 118 :1326-1345
[34]   The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review [J].
Nichetti, Federico ;
Marra, Antonio ;
Corti, Francesca ;
Guidi, Alessandro ;
Raimondi, Alessandra ;
Prinzi, Natalie ;
Braud, Filippo de ;
Pusceddu, Sara .
TARGETED ONCOLOGY, 2018, 13 (03) :333-351
[35]   The immunohistochemical diagnosis of mesothelioma -: A comparative study of epithelioid mesothelioma and lung adenocarcinoma [J].
Ordóñez, NG .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (08) :1031-1051
[36]   Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches [J].
Palaia, Innocenza ;
Tomao, Federica ;
Sassu, Carolina Maria ;
Musacchio, Lucia ;
Panici, Pierluigi Benedetti .
ONCOTARGETS AND THERAPY, 2020, 13 :6109-6129
[37]   RecQ helicase BLM regulates prostate cancer cell proliferation and apoptosis [J].
Qian, Xiaosong ;
Feng, Sujuan ;
Xie, Dawei ;
Feng, Dalin ;
Jiang, Yihang ;
Zhang, Xiaodong .
ONCOLOGY LETTERS, 2017, 14 (04) :4206-4212
[38]   Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis [J].
Qian, Xin ;
Chen, Hankui ;
Wu, Xiaofeng ;
Hu, Ling ;
Huang, Qi ;
Jin, Yang .
CYTOKINE, 2017, 89 :34-44
[39]   CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set [J].
Reinhold, William C. ;
Sunshine, Margot ;
Liu, Hongfang ;
Varma, Sudhir ;
Kohn, Kurt W. ;
Morris, Joel ;
Doroshow, James ;
Pommier, Yves .
CANCER RESEARCH, 2012, 72 (14) :3499-3511
[40]   Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery [J].
Scholler, Nathalie ;
Garvik, Barbara ;
Hayden-Ledbetter, Martha ;
Kline, Toni ;
Urban, Nicole .
CANCER LETTERS, 2007, 247 (01) :130-136
123456